Topical azelastine in perennial allergic conjunctivitis

References

• Bhargava A, Jackson W, El-Defrawy S. Ocular allergic disease. Drugs Today 1998;34(11):957–71
   PubMed Web of Science ®Google Scholar
• Dart JK, Buckley RJ, Monnickendan M, Prasad J. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis. Trans Ophthalmol Soc UK 1986;105(Pt 5):513–20
   PubMedGoogle Scholar
• Friedlaender M. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol 1993;38(Suppl):105–15
   PubMed Web of Science ®Google Scholar
• Buckley RJ. Allergic eye disease – a clinical challenge. Clin Exp Allergy 1998;28(Suppl 6):39–43
   PubMedGoogle Scholar
• Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103(3 Pt 1):401–7
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, Bagnasco M, Canonica GW. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96(6 Pt 1):971–9
   PubMed Web of Science ®Google Scholar
• Foster CS. The pathophysiology of ocular allergy: current thinking. Allergy 1995;50(21):6–9, discussion 34–8
   PubMed Web of Science ®Google Scholar
• Mösges R, Hassan H, Wenzel M. Optimal use of topical agents for allergic conjunctivitis. BioDrugs 1997;8(4):250–64
   PubMed Web of Science ®Google Scholar
• González, MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 1998;36(5):292–300
   PubMed Web of Science ®Google Scholar
• Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH. Antihistamines: topical vs oral administration. Clin Exp Allergy 1996;26(Suppl 3):11–17
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27(2):182–91
   PubMed Web of Science ®Google Scholar
• Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomised, placebo-controlled study. Allergy 1998;53(9):857–62
   PubMed Web of Science ®Google Scholar
• Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol 1998;8(4):207–16
   PubMed Web of Science ®Google Scholar
• Buscaglia S, Paolieri F, Catrullo A, Fiorino N, Riccio AM, Pesce G, Montagna P, Bagnasco M, Ciprandi G, Canonica GW. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro. Clin Exp Allergy 1996;26(10):1188–96
   PubMed Web of Science ®Google Scholar
• Abelson MB, Weintraub D. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 1994;4(2):91–101
   PubMedGoogle Scholar
• Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998;14(3):161–70
   PubMed Web of Science ®Google Scholar
• Lenhard G, Mivsek-Music E, Perrin-Fayolle M, Obtulowicz K, Secchi A. Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Curr Med Res Opin 1997;14(1):21–8
   PubMed Web of Science ®Google Scholar
• Horak F, Berger UE, Menapace R, Toth J, Stubner PU, Marks B. Dose-dependent protection by azelastine eye drops against pollen induced allergic conjunctivitis. A double-blind, placebo-controlled study. Arzneimittelforschung 1998;48(4):379–84
   PubMed Web of Science ®Google Scholar
• Giede C, Metzenauer P, Petzold U, Ellers-Lenz B. Comparison of azelastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000;16(3):153–63
   PubMed Web of Science ®Google Scholar
• Jogi R, Janson C, Bjornsson E, Boman G, Bjorksten B. Atopy and allergic disorders among adults in Tartu, Estonia compared with Uppsala, Sweden [see comments]. Clin Exp Allergy 1998;28(9):1072–80
   PubMed Web of Science ®Google Scholar
• Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995;50(2):208–21
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Catrullo A, Tosca M, Cerqueti P, Mondino C, Passalacqua G, Canonica GW. Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. J Investig Allergol Clin Immunol 1999;9(1):35–8
   PubMed Web of Science ®Google Scholar
• Gastpar H, Nolte D, Aurich R, Brendt P, Enzmann H, Giesemann G, Kunkel G, Petzold U, Renz W, Schata M, et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 1994;49(3):152–8
   PubMed Web of Science ®Google Scholar
• Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;38(Suppl):115–32
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36(5):329–52
   PubMed Web of Science ®Google Scholar